Abstracts by key term: Generic-capable drug market
It is currently becoming apparent that the discount agreements are reinforcing a development that leads to market results that do not do justice to the relative or absolute value of the medicines and thus lead to allocative inefficiencies. Against this background, a proposal for a central approach to controlling the generic drug market, based on a cost-benefit assessment, was developed. The core of the model is that the reimbursement prices in the statutory health insurance are set in such a way that they reflect the benefit ratio of the drugs to each other. In this way, the approach induces a needs-oriented and efficient distribution of scarce resources in drug supply. The approach also offers a pragmatic multi-step scenario with budget neutrality in the introduction phase of the model.